-

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, August 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/p5tuszv4. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BIbb7f6b70b4ce4820b6391059390d6139

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Tracy Morris
media@veracyte.com
(650) 380-4413

Veracyte, Inc.

NASDAQ:VCYT

Release Versions

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Tracy Morris
media@veracyte.com
(650) 380-4413

More News From Veracyte, Inc.

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time. Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 30 days following the conclu...

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Research Healthcare Conference – New York, NY Fireside Chat on November 17th at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference – London, UK Fireside Chat on November 20th at 11:30 a.m. Greenwich Mean Time Stephens Annual Investment Conference – Nashville, TN Fireside Chat on November 20t...

Veracyte Announces Third Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. “We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance,” said Marc Stapley, Veracyte’s chief executive officer. “We continue to advance our mission of transforming cancer care by generat...
Back to Newsroom